[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre de recherche du Centre hospitalier universitaire de Sherbrooke\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100405426","phase-2-68ga-dotatate-neuroblastoma-imaging-pilot-100405426",false,"NCT04559217","68Ga-DOTATATE Neuroblastoma Imaging Pilot","Pilot Study of 68Ga-DOTATATE PET\u002FCT and 123I-MIBG Scintigraphy Imaging of Neuroblastoma","Inclusion Criteria:\n\n* Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma\n* Planned 123I-MIBG imaging\n* Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent\u002Flegal tutor of the pediatric candidates)\n* Aged between 1 day and 21 years old (inclusively).\n\nExclusion Criteria:\n\n* History of another cancer in the past 5 years other than non-melanomatous skin cancer.\n* Currently under a randomized control trial with unknown allocation;\n* Currently under treatment;\n* Medical\u002Fsurgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET\u002FCT scan.\n* Medically unstable or unable to undergo scan.\n* Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).\n* Prior allergic reaction to somatostatin analogues","ALL","21 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET\u002FCT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.",[26],"Neuroblastoma",[28,29,30,31],"imaging","68Ga-Dotatate","68Ga-Octreotate","positron emission tomography (PET)","RECRUITING","2026-05-26",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":36},"2021-12-06",{"date":40,"type":20},"2028-09-30",{"name":42,"class":43},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100572366","phase-1-her2-pet-imaging-in-her2-low-breast-cancers-100572366","NCT06732336","HER2-PET Imaging in HER2-low Breast Cancers","HER2-PET Imaging Using 89Zr-trastuzumab in Low HER2-expressing (HER2-low) Breast Cancers","Inclusion Criteria:\n\n* HER2-low metastatic breast cancer;\n* At least 18 years-old ;\n* Able to stay in supine position for at least 30 minutes;\n* Written inform consent.\n\nExclusion Criteria:\n\n* Pregnancy or concomitant breast feeding;\n* Hepatic disorders such as cirrhosis, hepatitis, or any other liver condition judged as significant by the treating physician and that could impair the biliary excretion of 89Zr-trastuzumab;\n* Renal disorders considered significant by the treating physician and that could impair the normal elimination of 89Zr-trastuzumab;\n* Known hypersensitivity or allergy to trastuzumab, desferrioxamine, or any constituents of 89Zr-trastuzumab.","18 Years",{"count":54,"type":20},40,[56,23],"PHASE1","A strategy to target the oncogenic receptor HER2 using a version of the anti-HER2 therapeutic antibody trastuzumab coupled to desferrioxamine (DFO) and radiolabeled with zirconium-89 (\\[89Zr\\]-DFO-trastuzumab) has been successfully evaluated in our group in preclinical settings. Clinical studies by other groups in recent years have shown the potential of targeting HER2+ lesions with \\[89Zr\\]-DFO-trastuzumab in patients with HER2+ cancers. We now want to establish the diagnostic potential of a protocol adding \\[89Zr\\]-DFO-trastuzumab PET imaging to FDG PET already used in the clinic for the detection of HER2-expressing cancers, including low expression levels considered until now as HER2-negative (HER2-low, IHC score 1+ and 2+ without FISH amplification of the HER2 locus). The HER2-low status has recently gained relevance thanks to large studies showing the efficacy of immunotherapy combined with drugs such as Enhertu (trastuzumab-deruxtecan), while trastuzumab alone was traditionally only effective for HER2+ cancers (IHC score 2+\u002FFISH+, or 3+). In particular, we aim to develop a method to assess whole-body intertumoral heterogeneity in HER2 expression in order to detect cases with heterogeneous diseases and thus better stage patients and guide the optimal choice of personalized and targeted treatment to use. More specifically, the project aims to image with \\[89Zr\\]-DFO-trastuzumab PET patients with cancer, particularly breast cancer, but also esophageal, gastric, ovarian, endometrial and lung cancer, and whose primary tumor status is HER2-low.",[59],"Breast Cancer Metastatic",[61,62,63,64,65],"HER2","HER2-low","PET","Breast cancer","89Zr-trastuzumab","2026-03-30",{"date":68,"type":36},"2026-03-31",{"date":70,"type":36},"2024-12-01",{"date":72,"type":20},"2027-03-31",{"name":42,"class":43},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100427553","phase-3-68ga-dota-tate-petct-imaging-in-nets-100427553","NCT04847505","68Ga-DOTA-TATE PET\u002FCT Imaging in NETs","Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management","Inclusion Criteria:\n\n1. Clinical requisition for a 68Ga-DOTA-TATE PET\u002FCT signed by a referring doctor\n2. Patients with suspected or proven tumors expressing somatostatin receptors\n3. Informed consent by patient (or parents if patient is less than 18 years of age)\n\nExclusion Criteria:\n\n1. \\*Pregnancy (not an absolute exclusion). See below\\*.\n2. Patient refusal to participate.\n3. Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.\n\n   * In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an in-depth discussion with the treating physicians and the patient. In this context, any clinical situation in which the patient's life would be at stake by excluding her from the study would be considered. The conditions to decide whether to include the patient would be:\n\n     * Severe medical condition involving the life of the pregnant woman and\u002For the fetus;\n     * Existing treatments that are ineffective or may present toxicity to the woman and\u002For fetus;\n     * High clinical suspicion of a somatostatin receptor overexpressing tumour;\n     * Negative, indeterminate or contraindicated first-line imaging tests;\n     * Therapeutic gesture considered during pregnancy based on the results of the examination, which may include termination of pregnancy or premature delivery;\n     * Documented discussion with the treating team and the patient;\n     * Patient agrees.",{"count":83,"type":20},5000,[85],"PHASE3","This clinical trial is a pragmatic study aiming to evaluate the innocuity\u002Fsafety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine cancer patients. It is a single-center study, but with recruitment across all Canada. The trial is prospective, non-randomized, open-label and with no control group. The superiority of this procedure over the former standard-of-care (Octreoscan) was already established in previous and numerous studies across the world. As such, the current trial aims to gather data to further support the implementation of 68Ga-DOTA-TATE as the new standard-of-care for neuro-endocrine tumors (NET).",[88],"Neuroendocrine Tumors",[90,91,92,93],"68Ga-DOTA-TATE","PET imaging","Pragmatic study","Neuroendocrine tumors (NET)","2024-07-16",{"date":96,"type":36},"2024-07-18",{"date":98,"type":36},"2020-01-01",{"date":100,"type":20},"2025-12-31",{"name":42,"class":43},2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":74},"100456785","68ga-psma-617-petct-for-psma-expressing-tumor-a-pragmatic-study-100456785","NCT05228106","68Ga-PSMA-617 PET\u002FCT for PSMA-expressing Tumor: a Pragmatic Study","Pragmatic Study on the Use of 68Ga-PSMA-617 PET\u002FCT Imaging as a Standard of Care to Influence Clinical Management of Tumors Overexpressing PSMA.","Inclusion Criteria:\n\n1. Clinical requisition for a 68Ga-PSMA-617 PET\u002FCT signed by a referring doctor;\n2. Patients with suspected, proven or prior tumor expressing PSMA;\n3. Informed consent by patient.\n\nExclusion Criteria:\n\n1. Patient refusal to participate;\n2. Prior severe anaphylactic reaction to 68Ga-PSMA-617 .",{"count":111,"type":20},1000,"OBSERVATIONAL","This project aims to monitor the innocuity\u002Fsafety profile of cyclotron-produced \\[68Ga\\]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label study, with no control group. Although prostate cancers constitute the usual recommended population for this PET modality, recent evidences suggest that most solid tumors express substantial amount of PSMA in their neovasculature. As such, all cancers (excluding non-solid cancers) will be eligible for \\[68Ga\\]-PSMA-617 PET imaging in this trial, for as long as their tumors express PSMA.\n\nThis study also aims to instigate the use of \\[68Ga\\]-PSMA-617 in the routine standard-of-care for detection and follow-up of eligible cancers. FInally, this project seeks to gather information about the impact on patient management this novel PET modality will have over the current standard-of-care.",[115],"Solid Cancers",[117,91,92,118],"[68Ga]-PSMA-617","PSMA-expressing cancers","2024-02-05",{"date":121,"type":36},"2024-02-07",{"date":123,"type":36},"2022-01-21",{"date":125,"type":20},"2027-01-31",{"name":42,"class":43},""]